menu
    • menu
    [{"orgOrder":0,"company":"Tripoint Therapeutics","sponsor":"SPARC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tripoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tripoint Therapeutics \/ Tripoint Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tripoint Therapeutics \/ Tripoint Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Tripoint Therapeutics

    Menu

    Tripoint Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tripoint Therapeutics

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Tripoint Therapeutics

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levetiracetam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : SPARC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sparc Licenses Commercialization Rights of Elepsia Drug to Tripoint Therapeutics

                            Details : Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and El...

                            Product Name : Elepsia

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : Levetiracetam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : SPARC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth